Gabriele Vassallo

Gabriele Vassallo

Auto-generated profile, based on publicly available information

Gabriele Vassallo

Department of Internal Medicine, Barone Lombardo Hospital, Canicattì, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2013 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
GAGiovanni Addolorato
Giovanni Addolorato
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
LLLorenzo Leggio
Lorenzo Leggio
AFAnna Ferrulli
Anna Ferrulli
CDCristina D'ANgelo
Cristina D'ANgelo
GGGemelli OLT Group
Gemelli OLT Group

10 February 2015 in Drugs
Verified
Journal Article
Closed access
PDF file
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
CDCristina D’aNgelo
Cristina D’aNgelo
AFAnna Ferrulli
Anna Ferrulli
GVGabriele Vassallo
Gabriele Vassallo
MAMariangela Antonelli
Mariangela Antonelli
GAGiovanni Addolorato
Giovanni Addolorato

23 March 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
GVG. Vassallo
G. Vassallo
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
AFAnna Ferrulli
Anna Ferrulli
MAM. Antonelli
M. Antonelli
RLR. Landolfi
R. Landolfi
GAGiovanni Addolorato
Giovanni Addolorato

11 November 2013 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
KSKatrin Skala
Katrin Skala
FCFabio Caputo
Fabio Caputo
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
GVGabriele Vassallo
Gabriele Vassallo
MAMariangela Antonelli
Mariangela Antonelli
GAGiovanni Addolorato
Giovanni Addolorato
Sodium oxybate (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs. This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and EMBASE (searches last updated 20 September 2013), bibliographies from published literature, clinical trial registries/databases, and websites. SMO has proved safe and effective in the treatment of alcohol withdrawal syndrome and in the prevention of relapses. Craving for and abuse of SMO have been reported, in particular in some subtypes of alcoholic patients, e.g., those affected by co-addiction and/or psychiatric comorbidity. Future multicenter, multinational, randomized clinical trials should be useful to optimize the treatments in relation with patients' characteristics, for example, pharmacogenetic, neurobiological, and psychological.

8 July 2013 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
GAGiovanni Addolorato
Giovanni Addolorato
CDC. D'ANgelo
C. D'ANgelo
AFAnna Ferrulli
Anna Ferrulli
GVG. Vassallo
G. Vassallo
RLR. Landolfi
R. Landolfi
Background Persistent hiccup is a worrying symptom both for patients, because of reduced quality of life, and for physicians, because of frustration for unsuccessful treatments. Aim To test baclofen administration for the treatment of persistent hiccup. Method We report a series of seven patients affected by persistent hiccup successfully treated with baclofen. Results Hiccup stopped in all patients after a single administration of the drug. Conclusions Baclofen is a GABAB receptor agonist. It is conceivable that the reduction of dopamine release by GABAB receptor stimulation is able to interrupt hiccup's reflex arc.

23 July 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
Antonio MirijelloAntonio Mirijello
Antonio Mirijello
FCFabio Caputo
Fabio Caputo
GVGabriele Vassallo
Gabriele Vassallo
BRBenjamin Rolland
Benjamin Rolland
CTClaudia Tarli
Claudia Tarli
GAGiovanni Addolorato
Giovanni Addolorato
Almost 10% of the world’s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.